Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion type Assertion NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_head.
- NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion description "[Whereas BMI1 and RING1 are abundantly present in prostate cancer, EZH2 is expressed at relatively low levels, making it a less obvious target for therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_provenance.
- NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion evidence source_evidence_literature NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_provenance.
- NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion SIO_000772 17134822 NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_provenance.
- NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion wasDerivedFrom befree-2016 NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_provenance.
- NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_assertion wasGeneratedBy ECO_0000203 NP581701.RAd66PGRvFkjN-4PN0NwyllvBGYHNWe7uovbk-DhwBhPM130_provenance.